Reduced serum BDNF levels in patients with chronic schizophrenic disorder in relapse, who were treated with typical or atypical antipsychotics

World Journal of Biological Psychiatry

Volumn 11, Issue 2 PART 2, 2010, Pages 251-255

  Rizos, Emmanouil N ^a   Papadopoulou, Athanasia ^b   Laskos, Efstathios ^b   Michalopoulou, Panagiota G ^a,c   Kastania, Anastasia ^d   Vasilopoulos, Dimitrios ^b   Katsafouros, Konstantinos ^b   Lykouras, Lefteris ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b Athens Psychiatric Hospital Dromokaition   (Greece)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d BIOMEDICAL RESEARCH FOUNDATION   (Greece)

Author keywords

Atypical antipsychotics; Brain derived neurotrophic factor (BDNF); Olanzapine; Schizophrenia; Typical antipsychotics

Indexed keywords

AMISULPRIDE; BRAIN DERIVED NEUROTROPHIC FACTOR; HALOPERIDOL; OLANZAPINE; RISPERIDONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MEASUREMENT; RECURRENT DISEASE; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BRAIN-DERIVED NEUROTROPHIC FACTOR; CASE-CONTROL STUDIES; FEMALE; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; RISPERIDONE; SCHIZOPHRENIA; SULPIRIDE; TREATMENT FAILURE;

EID: 77950826973     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.3109/15622970802182733     Document Type: Article

References (40)

1. Altar CA, Cai N, Bliven T, Juhasz M, Conner JM, Acheson AL, et al. 1997. Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature 389(6653):856- 860.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. DSM IV. American Psychiatric Association. Washington, DC, 2000.
3. Angelucci F, Mathe AA, Aloe L. 2000. Brain-derived neurotrophic factor and tyrosine kinase receptor TrkB in rat brain are significantly altered after haloperidol and risperidone administration. J Neurosci Res 60:783-794.
4. Angelucci F, Mathé AA, Aloe L. 2004. Neurotrophic factors and CNS disorders: findings in rodent models of depression and schizophrenia. Prog Brain Res 146:151-165.
5. Angelucci F, Aloe L, Iannitelli A, Gruber SH, Mathe AA. 2005. Effect of chronic olanzapine treatment on nerve growth factor and brain-derived neurotrophic factor in the rat brain. Eur Neuropharmacology 15:311-317.
6. Bai O, Chlan-Fourney J, Bowen R, Keegan D, Li XM. 2003. Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs. J Neurosci Res 71:127-131.
7. Buckley P, Mahadick S, Pillai A, Terry A. 2007. Neurotrophins and schizophrenia. Schizophr Res 94:1-11.
8. Durany N, Michel T, Zochling R, Boissi KW, Cruz-Sánchez FF, Riederer P, et al. 2004. Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses. Schizophr Res; 52: 79-86.
9. Egan MF, Weinberger DR. 1997. Neurobiology of schizophrenia. Curr Opin Neurobiol 7:701-707.
10. First MB, Spitzer RL, Gibbon M, William JBM. Structured Clinical Interview for DSM-IV Axis I Disorders Patient Edition. Biometrics Research: New York 1997.
11. Guillain O, Diaz J, Carroll P, Griffon N, Schwartz JC, Sokoloff P. 2001. BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization. Nature 411:86-89.
12. Grillo RW, Ottoni G, Leke R, Souza DO, Portela LV, Lara DR. 2007. Reduced serum BDNF levels in schizophrenic patients on clozapine or typical antipsychotics. J Psychiatr Res 41:31-35.
13. Hall H, Lawyer G, Sillén A, Jönsson EG, Agartz I, Terenius L, et al. 2007. Potential genetic variants in schizophrenia: a Bayesian analysis. World J Biol Psychiatry 8:12-22.
14. Hori H, Yoshimura R, Yamada Y, Ikenouchi A, Mitoma M, Ida Y, et al. 2007. Effects of olanzapine on plasma levels of catecholamine metabolites, cytokines, and brain-derived neurotrophic factor in schizophrenic patients. Int Clin Psychopharmacol 22:21-27.
15. Karege F, Schwald M, Cisse M. 2002. Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neurosci Lett 328:261-264.
16. Kay SR, Opler LA, Lindenmayer JP 1987. The Positive and Negative Syndrome Scale (PANSS): rational and standardization. Br J Psychiatry; 155 (Suppl. 7):59-65.
17. Kim T-S, Kim D-J, Lee H, Kim Y-K. 2007. Increased plasma brain-derived neurotrophic factor levels in chronic smokers following unaided smoking cessation. Neurosci Lett 423:53-57.
18. Lieberman JA, Tollefson GD, Charles C, Zipurski R, Sharma T, Kahn RS, et al. 2005. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry 62:361-370.
19. Lieberman JA. 2006. Neurobiology and the natural history of schizophrenia. J Clin Psychiatry 67:e14.
20. Maisonpierre PC, Le Beau MM, Espinosa R 3rd, Ip NY, Belluscio L, de la Monte SM et al. 1991. Human and rat brain-derived neurotrophic factor and neurotrophin-3: gene structures, distributions, and chromosomal localizations. Genomics 10:558- 568.
21. Mathalon DH, Sullivan EV, Lim KO, Pfefferbaum A. 2001. Progressive brain volume changes and the clinical course of schizophrenia in men: a longitudinal magnetic resonance imaging study. Arch Gen Psychiatry 58:148-157.
22. Pan W, Banks WA, Fasold MB, Bluth J, Kastin A. 1998. Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology 37:1553-1561.
23. Pantelis C, Velakoulis D, McGorry PD, Wood SJ, Sucking J, Philips LJ, et al. 2003. Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet 361:281-288.
24. Parikh V, Evans D, Khan M, Mahadick S. 2003. Nerve growth factor in never-medicated first-episode psychotic and medicated chronic schizophrenic patients: possible implications for treatment outcome. Schizophr Res 60:117-123.
25. Parikh V, Khan MM,Mahadick SP. 2004. Olanzapine counteracts reduction of brain-derived neurotrophic factor and TrkB receptors in rat hippocampus produced by haloperidol. Neurosci Lett 356:135-139.
26. Pillai A, Terry AV Jr, Mahadick SP. 2006. Differential effects of long-term treatment with typical and atypical antipsychotics on NGF and BDNF levels in rat striatum and hippocampus. Schizophr Res 82:95-106.
27. Pirildar S, Gonul AS, Taneli F, Akdeniz F. 2004. Low serum levels of brain-derived neurotrophic factor in patients with schizophrenia do not elevate after antipsychotic treatment. Prog Neuropsychopharmacol Biol Psychiatry 28:709-713.
28. Rizos E, Rontos I, Laskos E, Arsenis G, Michalopoulou P-G, Vasilopoulos D, et al. 2008. Investigation of serum BDNF levels in drug-native patients with schizophrenia. Progr Neuro-Psychopharmacol Biol Psychiatry April 2008.
29. Shoval G, Weizman A. 2005. The possible role of neurotrophins in the pathogenesis and therapy of schizophrenia. Eur Neuropsychopharmacol 15:19-329.
30. Suwa M, Kishimoto H, Nofuji Y, Nakano H, Sasaki H, Radak Z, et al. 2006. Serum brain-derived neurotrophic factor level is increased and associated with obesity in newly diagnosed female patients with type 2 diabetes mellitus. Metab Clin Exp 55:852-857.
31. Takahashi M, Shirakawa O, Toyooka K, Kitamura N, Hashimoto T, Maeda Koizumi S, et al. 2000. Abnormal expression of brain-derived neurotrophic factor and its receptor in the corticolimbic system of schizophrenic patients. Mol Psychiatry 5:293-300.
32. Tan YL, Zhou DF, Cao LY, Zhang XY. 2005. Decreased BDNF in serum of patients with chronic schizophrenia on long-term treatment with antipsychotics. Neurosci Lett 382:27-32.
33. Thoenen H. 1995. Neurotrophins and neuronal plasticity. Science 270 593-598.
34. Toyooka K, Asama K, Watanabe Y, Muratake T, Takahashi M, Someya T, et al. 2002. Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients. Psychiatry Res 110:249-257.
35. Velakoulis D, Wood SJ, Wong MT, McGorry PD, Yung A, Philips L, et al. 2006. Hippocampal and amygdala volumes according to psychosis stage and diagnosis: a magnetic resonance imaging study of chronic schizophrenia, first episode psychosis, and ultra-high-risk individuals. Arch Gen Psychiatry 63:139-149.
36. Vidal CN, Rapoport JL, Hayashi KM, Geaga JA, Sui Y, McLemore LE, et al. 2006. Dynamically spreading frontal and cingulated deficits mapped in adolescents with schizophrenia. Arch Gen Psychiatry 63:25-34.
37. Wyatt RJ. 1991. Neuroleptics and the natural course of schizophrenia. Schizophr Bull 17:325-351.
38. Weickert CS, Hyde TM, Lipska BK, Herman MM, Weinberger DR, Kleinman JE. 2003. Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. Mol Psychiatry 8:592-610.
39. Weickert CS, Ligons DL, Romanczyk T, UngaroG, Hyde TM, Herman MM, et al. 2005. Reductions in neurotrophin receptor mRNAs in the prefrontal cortex of patients with schizophrenia. Mol Psychiatry 10:637-650.
40. Yoshimura R, Hori H, Sugita A, Ueda N, Kakihara S, Umene W, et al. 2007. Treatment with risperidone for 4 weeks increased plasma 3-methoxy-4- hydroxyphenylglycol (MHPG) levels, but did not alter plasma brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients. Progr Neuro-Psychopharmacol Biol Psychiatry 31:1072-1077.